Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Celgene
About this study
The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cancer.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (33)
| Palo Verde Hematology Oncology | Glendale, Arizona, United States | — |
| UCLA Hematology Oncology | Los Angeles, California, United States | — |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | — |
| University Cancer and Blood Center, LLC | Athens, Georgia, United States | — |
| Research Medical Center | Kansas City, Missouri, United States | — |
| Washington Univ School of Medicine | St Louis, Missouri, United States | — |
| North Shore Hematology Oncology Associates | East Setauket, New York, United States | — |
| Local Institution - 006 | New York, New York, United States | — |
| NYU Langone Medical Center | New York, New York, United States | — |
| Vanderbilt Univ Medical Center | Nashville, Tennessee, United States | — |
| Local Institution - 204 | Lyon, France | — |
| Local Institution - 200 | Marseille, France | — |
+ 21 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02546986